Tacrolimus 0,5 Teva, Tacrolimus 1 Teva, Tacrolimus 5 Teva 0,5 mg/ 1,0 mg/ 5,0 mg Capsules
PDF Leaflet Revision Date: 9 September 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Primary immunosuppression in transplant recipients.
Dosage (summary)
Initial oral dose: 0.10-0.40 mg/kg/day in two divided doses.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly population
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Ciclosporin
- Grapefruit juice
Contraindications
- Hypersensitivity to tacrolimus
- Pregnancy
- Concomitant administration of live vaccines
Common side effects
- Infections
- Nephrotoxicity
- Hypertension
- Diabetes mellitus
- Tremor
Counselling Points
- Monitor for signs of infection
- Avoid grapefruit juice
- Take on an empty stomach
- Report visual changes
Serious warnings
- Risk of serious infections
- Nephrotoxicity
- QT-prolongation
- Lymphoproliferative disorders
Important Disclaimer
The Tacrolimus 0,5 Teva, Tacrolimus 1 Teva, Tacrolimus 5 Teva 0,5 mg/ 1,0 mg/ 5,0 mg Capsules professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
